Tools

Ihsan Solaroglu, John H Zhang
  1. Zhang Neuroscience Research Laboratories, Loma Linda University School of Medicine, Loma Linda, CA 92350 USA
  2. Department of Neurosurgery, Ankara Atatügrk Research and Education Hospital, Ankara 06800, Turkey

Correspondence Address:
John H Zhang
Zhang Neuroscience Research Laboratories, Loma Linda University School of Medicine, Loma Linda, CA 92350 USA

DOI:10.4103/2152-7806.68706

© 2010 Solaroglu I This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article: Solaroglu I, Zhang JH. The microRNAs: Small size, big value,…. Surg Neurol Int 25-Aug-2010;1:45

How to cite this URL: Solaroglu I, Zhang JH. The microRNAs: Small size, big value,…. Surg Neurol Int 25-Aug-2010;1:45. Available from: http://sni.wpengine.com/surgicalint_articles/the-micrornas-small-size-big-value/

Date of Submission
03-Aug-2010

Date of Acceptance
05-Aug-2010

Date of Web Publication
25-Aug-2010

WHAT IS MIRNAS ROLE IN THE FUTURE NEUROSURGERY?

During the past decade, the role of miRNAs in a variety of pathological processes including neuronal development, apoptosis, inflammation, and angiogenesis has been discovered. A few studies assessed the role of miRNAs in Alzheimer disease and amyotrophic lateral sclerosis. However, a significant attention has been focused on the role of miRNAs in brain tumor development and progression.

Although still not well characterized, recent evidences indicate that miRNAs can function as tumor suppressors and oncogenes, and may have a central role in tumorigenesis. For example, it is well established that both epidermal growth factor receptor (EGFR) and the phosphatidylinositol 3-kinase (PI3K)/Akt pathways play a major role in the pathogenesis of human gliomas. In glioblastoma multiforme (GBM), EGFR overexpression and/or expression of its constitutively activated variant, EGFRvIII, result in the downstream activation of the PI3K/Akt pathway. The Akt activation is correlated with the increased tumorigenicity and invasiveness in gliomas. It has been shown that miR-7 potently and directly regulates EGFR, and the Akt pathway is directly inhibited by miR-7. The Notch pathway, which also plays an important role in glioma cell survival, has been shown to be inhibited by miR-326.[ 4 5 ]

Moreover, aberrant expression of miRNAs has also been shown to be involved in tumorigenesis. EGFR amplification and phosphatase tensin homolog on chromosome ten (PTEN) loss are two common genetic alterations seen in gliomas. PTEN, a tumor suppressor gene, is lost in up to 70% of glioblastomas. Downregulation of miR-21 with a specific antisense oligonucleotide inhibits EGFR pathway and suppresses the growth of human GBM cells, independent of PTEN status.[ 11 ] Exploring the underlying mechanisms of miRNA action in glioma biology will provide novel therapeutic targets, and will be useful for the clinical management of this lethal and devastating neurological disorder. The miRNAs have a role not only in glioma biology, but also in medulloblastoma tumorigenesis. A recent study showed the association between cyclin dependent kinase 6 (CDK6) and miR-124 in medulloblastoma cell lines. It has been shown that miR-124 is significantly decreased in medulloblastoma cells. The re-expression of miR-124 in medulloblastoma cells decreased expression of CDK6 protein, which is known to be an important regulator of cell cycle progression.[ 8 ] It is important to note that overexpression of CDK6 has been shown to correlate significantly with poor prognosis in medulloblastoma. Moreover, there is an increasing interest in an association between miRNA expression in brain tumors and chemo- and radiosensitivity, prognosis, and invasiveness. Not surprisingly, these results may provide the grounds for new therapeutic strategies in central nervous system (CNS) tumors in the near future. However, the puzzle is waiting to be solved.

As summary, the miRNAs contribute to various cellular processes, but the detailed mechanisms remain poorly understood. A detailed knowledge of the biogenesis, functions, and targets of miRNAs would be important for a better understanding of their potential in the treatment or prevention of CNS disorders.

References

1. Cho WC. OncomiRs: The discovery and progress of microRNAs in cancers. Mol Cancer. 2007. 6: 60-

2. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009. 19: 92-105

3. Grosshans H, Slack FJ. Micro-RNAs small is plentiful. J Cell Biol. 2002. 156: 17-22

4. Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, Schmittgen T. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci. 2009. 29: 15161-8

5. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M. MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008. 68: 3566-72

6. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993. 75: 843-54

7. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005. 120: 15-20

8. Pierson J, Hostager B, Fan R, Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 2008. 90: 1-7

9. Turner JD, Williamson R, Almefty KK, Nakaji P, Porter R, Tse V. The many roles of microRNAs in brain tumor biology. Neurosurg Focus. 2010. 28: E3-

10. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008. 79: 581-8

11. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 2010. 90: 144-55

Leave a Reply

Your email address will not be published. Required fields are marked *